The SELINA study, sponsored by Boehringer Ingelheim, evaluated the safety and effectiveness of Trajenta (linagliptin) in a real-world setting among Korean patients with Type 2 Diabetes Mellitus. With a significant enrollment of 3,219 patients, the study provides valuable post-marketing data that can enhance the product's positioning in the competitive diabetes market in South Korea. Given the increasing prevalence of diabetes in Asia, the findings may support ongoing marketing efforts and inform future product development strategies. The collaboration with Eli Lilly indicates a strategic partnership that may enhance market access and distribution capabilities.